O TYM ODCINKU
What if you could know before a clinical trial which patients will respond? Not after Phase 2 fails. Not after spending $50M. Before you even start.
In this episode, Pilgrim Jackson, CEO of Yatiri Bio, shares how his company is using proteomics to predict treatment response in AML and ovarian cancer with 100% accuracy so far.
What we discuss:
• How proteomic signatures differentiate responders from non-responders in AML and ovarian cancer
• Why this could reduce Phase 2 trial enrollment from 100 patients to 40—cutting costs in half
• De-risking clinical trial design and addressing patient heterogeneity
• Regulatory considerations for biomarker-driven and stratified trials
• The future of precision oncology and patient-centric trial design
This isn't incremental improvement. This is a completely different way to run trials.
About the Guest: Pilgrim Jackson is CEO of Yatiri Bio, a biotechnology company decoding proteins to predict treatment response in oncology.
About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.
🔗 Connect:
• Yatiri Bio: [https://yatiribio.com]
• Pilgrim Jackson:[https://www.linkedin.com/in/pilgrimjackson]
• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]
📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]
#Biotech #ClinicalTrials #PrecisionMedicine #Proteomics #Oncology #AML #DrugDevelopment
